Saturday 17 October 2026
Export BMRN’s income statement to Excel — free account
BioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024. In the quarter to June 2026, revenue grew 19.9%, EPS fell 81.6%, free cash flow fell 20.3% and total debt rose 602.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
54.68
1.37
−2.44%
Follow BMRN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 18.58 | 0.00 | 130.66 | 110.17 | 29.21 | 32.65 |
Piotroski F-Score |
4 | 4 | 6 | 6 | 4 | 4 | 8 | 6 | 8 | 5 |
P/S ratio |
12.76 | 12.09 | 10.11 | 8.88 | 8.52 | 8.75 | 8.89 | 7.61 | 4.38 | 3.54 |
Altman Z-Score |
5.94 | 5.25 | 6.32 | 5.83 | 5.93 | 5.96 | 7.14 | 6.38 | 6.68 | 5.67 |
P/FCF ratio |
0.00 | 697.39 | 298.03 | 0.00 | 1,056.63 | 87.18 | 126.21 | 356.59 | 25.73 | 15.90 |
Altman Z″-Score (non-manufacturers) |
1.34 | 2.41 | 2.97 | 2.16 | 4.02 | 3.87 | 4.72 | 4.34 | 7.30 | 7.43 |
Beneish M-Score |
(2.74) | (2.58) | (2.26) | (2.39) | (1.55) | (2.93) | (2.33) | (2.14) | (2.44) | (2.49) |
P/Operating CF |
(67,848.34) | 1,086.50 | 305.36 | 263.99 | (1,184.60) | 1,444.99 | 2,746.77 | 670.13 | 67.29 | 114.39 |
P/B ratio |
5.15 | 5.65 | 5.08 | 4.85 | 3.86 | 3.79 | 4.05 | 3.72 | 2.21 | 1.87 |
Price to Tangible BV |
7.07 | 7.58 | 6.62 | 6.13 | 4.54 | 4.39 | 4.58 | 4.13 | 2.40 | 2.01 |
EV/Sales |
12.66 | 11.92 | 10.19 | 8.94 | 8.53 | 8.79 | 8.80 | 7.62 | 4.36 | 3.39 |
EV/EBITDA |
0.00 | 205.36 | 0.00 | 5,358.31 | 254.84 | 526.05 | 69.33 | 65.60 | 21.74 | 22.57 |
EV/Operating CF |
(62.07) | (1,787.89) | 752.03 | 315.61 | 185.98 | 53.29 | 104.84 | 115.73 | 21.72 | 13.20 |
EV/FCF |
(40.24) | 687.66 | 300.41 | (168.97) | 1,058.08 | 87.58 | 124.87 | 356.84 | 25.63 | 15.24 |
Quick Ratio |
2.29 | 2.03 | 2.73 | 1.21 | 3.07 | 2.54 | 2.98 | 1.45 | 2.96 | 3.25 |
Current Ratio |
3.24 | 2.70 | 3.93 | 2.08 | 4.76 | 4.16 | 4.67 | 2.51 | 5.33 | 5.21 |
Net Debt/EBITDA |
0.15 | (2.91) | 9.23 | 33.17 | 0.35 | 2.44 | (0.75) | 0.05 | (0.95) | (1.99) |
Debt/Assets |
16.98% | 25.35% | 18.76% | 18.08% | 18.59% | 18.14% | 17.15% | 15.89% | 8.52% | 7.86% |
Debt/Equity |
0.25 | 0.42 | 0.28 | 0.27 | 0.26 | 0.26 | 0.24 | 0.22 | 0.11 | 0.10 |
Asset Turnover |
0.29 | 0.30 | 0.33 | 0.37 | 0.35 | 0.31 | 0.34 | 0.37 | 0.41 | 0.44 |
Operating CF/Net income |
0.36 | 0.07 | (0.26) | (2.02) | 0.10 | (4.75) | 1.24 | 0.95 | 1.34 | 2.37 |
Capex/Depreciation |
(1.51) | (0.82) | (0.99) | (1.34) | (0.67) | (1.05) | (0.27) | (1.13) | (0.99) | (1.48) |
Interest Coverage |
(20.34) | (0.34) | (2.83) | (4.28) | (1.48) | (5.37) | 10.08 | 10.72 | 38.23 | 37.57 |
| (24.39%) | (4.20%) | (2.67%) | (0.78%) | 23.63% | (1.53%) | 3.19% | 3.51% | 8.05% | 5.94% | |
| (16.26%) | (2.70%) | (1.70%) | (0.52%) | 16.21% | (1.08%) | 2.29% | 2.54% | 6.17% | 4.79% | |
ROIC |
(18.88%) | (0.36%) | (2.84%) | (1.95%) | (0.66%) | (1.19%) | 2.28% | 2.34% | 5.92% | 5.00% |
Return on Tangible Assets |
(35.38%) | (5.12%) | (3.11%) | (1.18%) | 29.63% | (2.32%) | 4.37% | 5.89% | 11.64% | 8.41% |
Average Days of Receivables |
70.36 | 72.62 | 83.87 | 80.84 | 87.96 | 73.82 | 80.33 | 95.61 | 84.48 | 102.91 |
Research and Development Expense of Revenue |
59.27% | 46.49% | 46.70% | 41.96% | 33.76% | 34.06% | 30.99% | 30.87% | 26.18% | 28.62% |
Selling, General and Administrative Expense of Revenue |
42.67% | 42.20% | 40.53% | 39.96% | 39.65% | 41.13% | 39.28% | 36.89% | 35.36% | 35.79% |
Intangible Assets out of Total Assets |
0.19 | 0.15 | 0.16 | 0.14 | 0.10 | 0.10 | 0.08 | 0.07 | 0.06 | 0.05 |
Share Based Compensation of Revenue |
12.06% | 10.68% | 9.98% | 9.38% | 10.20% | 10.68% | 9.37% | 8.56% | 7.06% | 5.63% |
Graham Net Nets |
0.01 | 0.02 | 0.04 | 0.02 | 0.04 | 0.03 | 0.05 | 0.06 | 0.15 | 0.21 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 49.11 | 0.00 | 20.75 | 22.98 | 38.82 | 36.05 |
Earnings Yield |
(4.58%) | (0.73%) | (0.50%) | (0.17%) | 5.38% | (0.40%) | 0.77% | 0.91% | 3.42% | 3.06% |
Free Cash Flow Yield |
(2.47%) | 0.14% | 0.34% | (0.60%) | 0.09% | 1.15% | 0.79% | 0.28% | 3.89% | 6.29% |
Revenue per Share |
6.73 | 7.53 | 8.42 | 9.52 | 10.29 | 10.10 | 11.31 | 12.88 | 15.02 | 16.80 |
Operating CF per Share |
(1.37) | (0.05) | 0.11 | 0.27 | 0.47 | 1.67 | 0.95 | 0.85 | 3.01 | 4.32 |
Capex per Share |
(0.89) | (0.43) | (0.53) | (0.77) | (0.39) | (0.65) | (0.15) | (0.57) | (0.46) | (0.58) |
Free Cash Flow per Share |
(2.27) | (0.48) | (0.42) | (0.50) | 0.08 | 1.01 | 0.80 | 0.28 | 2.55 | 3.74 |
Cash per Share |
4.76 | 8.00 | 6.12 | 4.21 | 5.89 | 5.54 | 6.97 | 5.72 | 5.99 | 8.14 |
Shareholders Equity per Share |
16.67 | 16.10 | 16.76 | 17.44 | 22.71 | 23.33 | 24.85 | 26.36 | 29.77 | 31.74 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
16.67 | 16.10 | 16.76 | 17.44 | 22.71 | 23.33 | 24.85 | 26.36 | 29.77 | 31.74 |
Free Cash Flow |
(376.22) | (82.98) | (74.41) | (90.14) | 15.01 | 185.31 | 147.69 | 51.65 | 485.42 | 717.02 |
Working Capital |
982.48 | 1,390.63 | 1,532.97 | 1,009.64 | 1,849.67 | 1,727.89 | 2,162.57 | 1,779.06 | 2,625.44 | 3,194.46 |
Capital Expenditures |
(148.38) | (74.22) | (94.62) | (138.41) | (70.36) | (119.22) | (28.21) | (107.61) | (87.42) | (110.97) |
Net Current Asset Value |
164.38 | 382.68 | 597.03 | 374.49 | 600.20 | 535.28 | 979.54 | 1,066.03 | 1,901.48 | 2,446.47 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 114.56 | 99.21 | 25.70 | 26.69 |
Capex to Sales |
0.13 | 0.06 | 0.06 | 0.08 | 0.04 | 0.06 | 0.01 | 0.04 | 0.03 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 115.79 | 99.14 | 25.80 | 27.84 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.12 | 0.10 | 0.10 | 0.10 | 0.10 | 0.11 | 0.10 | 0.09 | 0.08 | 0.08 |
Cash ROIC |
(8.87%) | (1.54%) | (1.52%) | (1.91%) | 0.24% | 2.91% | 2.11% | 0.73% | 6.57% | 8.70% |
Accounts Receivable Turnover |
5.87 | 5.51 | 4.94 | 4.73 | 4.51 | 4.49 | 5.02 | 4.42 | 4.41 | 4.11 |
Accounts Payable Turnover |
0.55 | 0.63 | 0.75 | 0.71 | 0.99 | 0.95 | 0.94 | 0.85 | 0.90 | 1.05 |
Inventory Turnover |
0.67 | 0.58 | 0.63 | 0.59 | 0.76 | 0.64 | 0.60 | 0.53 | 0.50 | 0.57 |
Average Days of Payables |
645.14 | 606.74 | 506.28 | 579.41 | 342.91 | 386.53 | 415.75 | 468.65 | 381.83 | 386.16 |
Days of Inventory on Hand |
618.36 | 718.23 | 614.62 | 690.75 | 486.33 | 602.50 | 648.76 | 759.54 | 775.41 | 660.81 |
Average Receivables |
190.12 | 238.32 | 302.00 | 360.02 | 412.88 | 410.88 | 417.36 | 547.51 | 647.12 | 784.37 |
Average Payables |
381.51 | 386.21 | 419.61 | 503.96 | 531.58 | 495.41 | 535.61 | 628.05 | 645.07 | 683.01 |
Average Inventory |
313.40 | 415.45 | 503.32 | 605.57 | 689.41 | 737.61 | 835.38 | 1,000.63 | 1,169.92 | 1,265.77 |
Average Assets |
3,876.53 | 4,328.41 | 4,530.13 | 4,558.58 | 5,269.03 | 5,926.40 | 6,189.92 | 6,608.34 | 6,915.27 | 7,291.48 |
Average Common Equity |
2,583.56 | 2,787.47 | 2,888.30 | 3,045.16 | 3,614.19 | 4,185.84 | 4,434.41 | 4,777.35 | 5,304.77 | 5,872.49 |
Columns are period end dates